These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 20331626)
61. Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin. Yuste L; Montero JC; Esparís-Ogando A; Pandiella A Cancer Res; 2005 Aug; 65(15):6801-10. PubMed ID: 16061662 [TBL] [Abstract][Full Text] [Related]
62. Context-dependent activation of Wnt signaling by tumor suppressor RUNX3 in gastric cancer cells. Ju X; Ishikawa TO; Naka K; Ito K; Ito Y; Oshima M Cancer Sci; 2014 Apr; 105(4):418-24. PubMed ID: 24447505 [TBL] [Abstract][Full Text] [Related]
63. Gene expression profiling of ATL patients: compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viability. Pise-Masison CA; Radonovich M; Dohoney K; Morris JC; O'Mahony D; Lee MJ; Trepel J; Waldmann TA; Janik JE; Brady JN Blood; 2009 Apr; 113(17):4016-26. PubMed ID: 19131553 [TBL] [Abstract][Full Text] [Related]
64. ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines. Ginestier C; Adélaïde J; Gonçalvès A; Repellini L; Sircoulomb F; Letessier A; Finetti P; Geneix J; Charafe-Jauffret E; Bertucci F; Jacquemier J; Viens P; Birnbaum D Oncogene; 2007 Nov; 26(50):7163-9. PubMed ID: 17525746 [TBL] [Abstract][Full Text] [Related]
65. Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance. Price-Schiavi SA; Jepson S; Li P; Arango M; Rudland PS; Yee L; Carraway KL Int J Cancer; 2002 Jun; 99(6):783-91. PubMed ID: 12115478 [TBL] [Abstract][Full Text] [Related]
66. Presence of HER4 associates with increased sensitivity to Herceptin in patients with metastatic breast cancer. Sassen A; Diermeier-Daucher S; Sieben M; Ortmann O; Hofstaedter F; Schwarz S; Brockhoff G Breast Cancer Res; 2009; 11(4):R50. PubMed ID: 19624808 [TBL] [Abstract][Full Text] [Related]
67. VDR/RXR and TCF4/β-catenin cistromes in colonic cells of colorectal tumor origin: impact on c-FOS and c-MYC gene expression. Meyer MB; Goetsch PD; Pike JW Mol Endocrinol; 2012 Jan; 26(1):37-51. PubMed ID: 22108803 [TBL] [Abstract][Full Text] [Related]
71. NOR1 Suppresses Cancer Stem-Like Cells Properties of Tumor Cells via the Inhibition of the AKT-GSK-3β-Wnt/β-catenin-ALDH1A1 Signal Circuit. Wang W; Yi M; Chen S; Li J; Zhang H; Xiong W; Li G; Li X; Xiang B J Cell Physiol; 2017 Oct; 232(10):2829-2840. PubMed ID: 27891591 [TBL] [Abstract][Full Text] [Related]
72. Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells. Camirand A; Lu Y; Pollak M Med Sci Monit; 2002 Dec; 8(12):BR521-6. PubMed ID: 12503030 [TBL] [Abstract][Full Text] [Related]
73. Human telomerase reverse transcriptase (hTERT) is a novel target of the Wnt/β-catenin pathway in human cancer. Zhang Y; Toh L; Lau P; Wang X J Biol Chem; 2012 Sep; 287(39):32494-511. PubMed ID: 22854964 [TBL] [Abstract][Full Text] [Related]
74. Differential roles for the coactivators CBP and p300 on TCF/beta-catenin-mediated survivin gene expression. Ma H; Nguyen C; Lee KS; Kahn M Oncogene; 2005 May; 24(22):3619-31. PubMed ID: 15782138 [TBL] [Abstract][Full Text] [Related]
75. Silencing mediator for retinoid and thyroid hormone receptor and nuclear receptor corepressor attenuate transcriptional activation by the beta-catenin-TCF4 complex. Song LN; Gelmann EP J Biol Chem; 2008 Sep; 283(38):25988-99. PubMed ID: 18632669 [TBL] [Abstract][Full Text] [Related]
76. Transcription factor TCF4 maintains the properties of human corneal epithelial stem cells. Lu R; Qu Y; Ge J; Zhang L; Su Z; Pflugfelder SC; Li DQ Stem Cells; 2012 Apr; 30(4):753-61. PubMed ID: 22232078 [TBL] [Abstract][Full Text] [Related]
77. Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin. Huang X; Gao L; Wang S; McManaman JL; Thor AD; Yang X; Esteva FJ; Liu B Cancer Res; 2010 Feb; 70(3):1204-14. PubMed ID: 20103628 [TBL] [Abstract][Full Text] [Related]
78. Sensitization of breast cancer cells to radiation by trastuzumab. Liang K; Lu Y; Jin W; Ang KK; Milas L; Fan Z Mol Cancer Ther; 2003 Nov; 2(11):1113-20. PubMed ID: 14617784 [TBL] [Abstract][Full Text] [Related]
79. Silencing of the Wnt transcription factor TCF4 sensitizes colorectal cancer cells to (chemo-) radiotherapy. Kendziorra E; Ahlborn K; Spitzner M; Rave-Fränk M; Emons G; Gaedcke J; Kramer F; Wolff HA; Becker H; Beissbarth T; Ebner R; Ghadimi BM; Pukrop T; Ried T; Grade M Carcinogenesis; 2011 Dec; 32(12):1824-31. PubMed ID: 21983179 [TBL] [Abstract][Full Text] [Related]
80. Activation of the Wnt/β-catenin pathway represses the transcription of the β-amyloid precursor protein cleaving enzyme (BACE1) via binding of T-cell factor-4 to BACE1 promoter. Parr C; Mirzaei N; Christian M; Sastre M FASEB J; 2015 Feb; 29(2):623-35. PubMed ID: 25384422 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]